Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein–Barr virus (EBV) by a quantitative real-time PCR assay

Friedrichs, Claudia; Neyts, Johan; Géczi, Gábor; Clercq, Erik De; Wutzler, Peter

doi:10.1016/j.antiviral.2003.12.005

Cited by 40 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all instances, the EBV evaluated was in standard laboratory cell lines, most often in P3HR1 cells, clones derived from it, Raji cells superinfected with P3HR1 virus, or B95-8 cells. [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] While such information is valuable for comparing the relative effectiveness of antiviral drugs, it is a step away from assessing the actual susceptibility of patients' strains and hence cannot be used to track development of antiviral resistance. The advantage of our assay is that it can test patient-derived EBV and hence may be useful for monitoring viral resistance especially in immunocompromised hosts receiving antiviral drugs for prevention or treatment of EBV diseases.…”

Section: Discussionmentioning

confidence: 99%

“…However, the procedures differ in several important ways, including the candidate antiviral drugs tested and the technique of quantifying 20 showed that IC 50 values using real-time TaqMan ® PCR were similar to those generated by DNA-DNA hybridization. Because PCR is easier to perform, it is destined to replace hybridization in IC 50 assays.…”

Section: H2g Concentration (µM) Proportion Of Ebv In Cells With Drug/mentioning

confidence: 99%

See 1 more Smart Citation

A method for evaluating antiviral drug susceptibility of Epstein-Barr virus

Romain¹,

Balfour²,

Vezina

et al. 2010

VAAT

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: H2g Concentration (µM) Proportion Of Ebv In Cells With Drug/mentioning

confidence: 99%

A method for evaluating antiviral drug susceptibility of Epstein-Barr virus

Romain¹,

Balfour²,

Vezina

et al. 2010

VAAT

View full text Add to dashboard Cite

“…) (Jung and Dorr, 1999) (Boyd et al, 1986) (Friedrichs et al, 2004) (Friedrichs et al, 2004) Pyrophosphate analogue Foscarnet, a phosphonoformic acid…”

Section: Introductionmentioning

confidence: 99%

Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies

Lee¹

2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Lymphoma is a type of cancer involving cells of the immune system, and has two major categories: Hodgkin lymphoma (HL) and all other lymphomas (non-HL). Although the two types may display the same symptoms, they are readily distinguishable via microscopic examination, and differ in the way they develop, spread and are treated. HL is a unique clinicopathological disorder characterized by the rare presence of malignant cells (usually accounting for 0.1% to 10% of the cells in the total tumor mass) in a background of a nonneoplastic cellular microenvironment comprising T-and Blymphocytes and other cell types (Weiss et al., 1999). In the United States, about 8,500 new cases of HL were expected to be diagnosed in 2010, and the overall incidence is increasing each year (Maggioncalda et al., 2011).Although the pathogenesis of HL is still largely unknown, the association of HL with Epstein-Barr virus (EBV) infection has been demonstrated in many reports. For examples, HL patients show elevated antibody titers to EBV antigens (Levine et al., 1971), and the risk of developing HL is increased up to three-fold in population that have experienced infectious mononucleosis caused by primary EBV infection (Gutensohn Over the past few decades, our understanding of the epidemiology and immunopathogenesis of Hodgkin lymphoma (HL) has made enormous advances. Consequently, the treatment of HL has changed signifi cantly, rendering this disease of the most curable human cancers. To date, about 80% of patients achieve long-term disease-free survival. However, therapeutic challenges still remain, particularly regarding the salvage strategies for relapsed and refractory disease, which need further identifi cation of better prognostic markers and novel therapeutic schemes. Although the precise molecular mechanism by which Epstein-Barr virus (EBV) contributes to the generation of malignant cells present in HL still remains unknown, current increasing data on the role of EBV in the pathobiology of HL have encouraged people to start developing novel and specifi c therapeutic strategies for EBVassociated HL. This review will provide an overview of therapeutic approaches for acute EBV infection and the classical form of HL (cHL), especially focusing on EBV-associated HL cases. and Cole, 1980), and EBV DNA/RNA can be detected in HL tissues (Brink et al., 1997), suggesting that as a primary event in the development of this disease, EBV infection may play a very crucial role in the pathogenesis of HL. AbstractAccording to a population-based cohort study, the frequency of EBV associated HL among total HL cases varies from 30 to 50% (in certain cases even higher; >90% in developing and underdeveloped countries, and >95% in HIV associated cases), and most of them appear in classical Hodgkin lymphoma (cHL), the major type of HL (Herbst et al., 1991;Pallesen et al., 1991;Ambinder et al., 1993;Leoncini et al., 1996). Since EBV is an oncogenic virus that is able to subvert cellular processes supporting growth and survival, the approach to unravel the f...

show abstract

“…At day 5 postinduction, total DNA was extracted (QIAamp DNA kit; Qiagen, Benelux BV, Venlo, Netherlands), and viral DNA was quantified by realtime quantitative PCR (qPCR) using an ABI Prism 7500 sequence detection system (Life Technologies). The sequences of the PCR primers for the detection of the target genes of KSHV (ORF73) and EBV (BNRF1) have been described elsewhere (18). The 50% and 90% effective concentrations (EC 50 and EC 90 ) were calculated by using regression analysis.…”

mentioning

confidence: 99%

“…Although no antiviral drugs are currently licensed for treatment of KSHV or EBV infections, several antiherpetic agents have been shown to inhibit these viruses in vitro, particularly those that target the viral DNA polymerase, such as acyclovir, ganciclovir, foscarnet, and HPMPC (18)(19)(20)(21)(22). Besides the inhibition of virus lytic replication, HPMPC elicits antitumor activity by induction of apoptosis, and this effect was also demonstrated against nasopharyngeal carcinoma (associated with EBV infection) xenografts in nude mice (23,24).…”

mentioning

confidence: 99%